We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
TRiCS
IV
TRiCSIV@leicester.ac.uk
Prof
Gavin
Murphy
gjm19@leicester.ac.uk
More information about this study, what is involved and how to take part can be found on the study website.
Ischaemic heart diseasesOther forms of heart diseaseComplications of surgical and medical care, not elsewhere classified
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Heart surgery is one of the most frequent surgical procedures and 50% of patients having heart surgery are < 65 years of age. During heart surgery, the use of a heart-lung machine and blood loss typically leads to anaemia. Anaemia occurs when there are lower than normal levels of red blood cells (RBCs) and haemoglobin, which carries oxygen to the rest of the body so that it can remain healthy and work properly. Anaemia could potentially lead to heart attack, kidney failure, stroke, or death.
To lower the risks associated with anaemia during and after heart surgery, there is a very high chance that patients will need to receive a red blood cell transfusion (meaning that donated blood will be provided to you through a vein in their arm).
A similar trial (TRICS III) was recently completed. It included about 5000 patients aged > 18 years undergoing heart surgery using the heart-lung machine, comparing the restrictive transfusion strategy to the liberal transfusion strategy. The results of this study showed that the restrictive transfusion strategy was favoured in elderly patients, but we don’t know yet which transfusion strategy is best for younger patients.
TRICS IV will help us see if there is a difference in health outcomes in patients between the ages of 18-65 who receive red blood cell transfusions based on the ‘liberal’ versus ‘restrictive’ transfusion strategies. The ’restrictive’ strategy will use a lower haemoglobin level, and the ‘liberal’ strategy will use a higher haemoglobin level for transfusion triggers. If a restrictive transfusion strategy in younger patients might lead to harm, a study is needed to make sure that these patients are given a transfusion at an appropriate haemoglobin level. If younger patients are not experiencing harm from a restrictive transfusion strategy, then they should not be exposed to the risk of being transfused unnecessarily.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Interventional type: Management of Care;Surgery;
You can take part if:
You may not be able to take part if:
1. Patients who refuse participation 2. Patients who are unable to receive or who refuse blood products 3. Patients who are involved in a preoperative autologous pre-donation program 4. Patients who are having a heart transplant or having surgery solely for an insertion of a ventricular assist device 5. Pregnancy or lactation (a negative pregnancy test must be obtained prior to randomisation for women of childbearing potential)
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Prof
Gavin
Murphy
gjm19@leicester.ac.uk
TRiCS
IV
TRiCSIV@leicester.ac.uk
More information about this study, what is involved and how to take part can be found on the study website.
The study is sponsored by MOUNT SINAI HOSPITAL (NY, USA) and funded by NIHR Evaluation, Trials and Studies Co-ordinating Centre (NETSCC) .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 56736
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
